No Data
No Data
CSPC Innovation Pharmaceutical's (SZSE:300765) Sluggish Earnings Might Be Just The Beginning Of Its Problems
CSPC Innovation Pharmaceutical: Half-year report for the year 2024.
CSPC Innovation Pharmaceutical: Summary of Half-Year Report in 2024.
Due to lower caffeine prices, CSPC Innovation Pharmaceutical's Q2 performance continued the downward trend from Q1. | Interpretations
Due to factors such as the decline in caffeine prices, CSPC Innovation Pharmaceutical's revenue and net income have both declined. Several pipelines in CSPC Innovation Pharmaceutical have made progress, and Enracuab monoclonal antibody has been conditionally approved for listing in June of this year. In order to enhance the industrialization capability of monoclonal antibody and ADCs, the company announced that CSPC Biotech will invest in the construction of two production line projects.
CSPC Innovation Pharmaceutical (300765.SZ): Jusheng Biotech plans to build a monoclonal antibody production line and ADC new product commercial production line, with a total investment of no more than 0.9 billion yuan.
CSPC Innovation Pharmaceutical (stock code 300765.SZ) announced that its subsidiary CSPC Pharma's Jusheng Bio-Pharmaceutical Co., Ltd. (referred to as ...
CSPC Innovation Pharmaceutical (300765.SZ): Net income in the first half of the year was 0.137 billion yuan, a YoY decrease of 48.27%.
CSPC Innovation Pharmaceutical (300765.SZ) released its 2024 interim report, with a reported revenue of 0.972 billion yuan, a year-on-year decrease of 27.71%; net income attributable to shareholders of the listed company was 0.137 billion yuan, a year-on-year decrease of 48.27%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.134 billion yuan, a year-on-year decrease of 65.87%; basic earnings per share was 0.10 yuan.
No Data